Search

… Tuesday, September 3, 2024 Dear MSK Community, Our knowledge of cancer — what it is and how it progresses — has developed at a staggering pace over the past 20 years. Today, thanks to remarkable advances in the understanding of how cancer cells behave and evolve, many led by MSK, researchers have devised

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

… Wednesday, April 27, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Jorge S. Reis-Filho Named a Susan G. Komen Scholar Jorge S. Reis-Filho Jorge S. Reis-Filho, MD, PhD, FRCPath, Chief, Experimental Pathology Service, was named a Susan G. Komen Scholar

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate disparities in cancer outcomes.

… Thursday, January 9, 2025 Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century have received that approval based on their ability to target genetic changes driving tumor growth. Medical oncologists use information about the genetic

Researchers from Memorial Sloan Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer.

… Friday, July 12, 2013 Researchers from Memorial Sloan Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer. Their findings are the result of a detailed review of genomic data that recently became

The MSK team’s goal was to get at the underlying defects in cells that these mutations cause.

… Monday, July 1, 2019 Summary MSK researchers have made new discoveries about how changes in a family of cancer-causing genes can lead to epigenetic changes. A family of genes called IDH are associated with cancer. These genes make enzymes called isocitrate dehydrogenases. The enzymes help break down

Laboratory studies have revealed an explanation for why androgen-deprivation therapy makes radiation therapy more effective in the treatment of high-risk prostate cancer.

… Thursday, December 12, 2013 Summary Laboratory studies have revealed an explanation for why androgen-deprivation therapy makes radiation therapy more effective in the treatment of high-risk prostate cancer. Sometimes a medical treatment becomes the standard of care before experts are able to explain

Stereotactic radiosurgery (SRS) is increasingly used to treat brain metastases. The technique uses advanced, computer-guided imaging to deliver a highly targeted and intense dose of photon radiation. Since the radiation dose conforms to the three-dimensional shape and size of the target lesion, there is minimal exposure to the rest of the brain and fewer side effects than with standard radiation techniques.

… Monday, March 24, 2025 Stereotactic radiosurgery (SRS) is increasingly used to treat brain metastases. The technique uses advanced, computer-guided imaging to deliver a highly targeted and intense dose of photon radiation. Since the radiation dose conforms to the three-dimensional shape and size of the

Twenty years ago, Charles Sawyers played a pivotal role in the development of Gleevec, a game-changing cancer drug that has gone on to save millions of lives and open doors for research and innovation. In this episode, Dr. Diane Reidy-Lagunes talks with Dr. Sawyers about what’s next in the field of cancer pharmaceuticals. Is another silver bullet on the horizon?

… Friday, December 17, 2021 The outlook used to be bleak for patients diagnosed with chronic myeloid leukemia (CML). But everything changed when the drug Gleevec® (imatinib) was developed 20 years ago and became a “silver bullet,” able to send CML into remission for years. Gleevec has saved millions of

A multi-institutional team led by investigators from Memorial Sloan Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies.

… Friday, October 1, 2010 Discovery Shows that Activating Rearrangements in Receptor Genes are More Common than Previously Thought Media Advisory A multi-institutional team led by investigators from Memorial Sloan Kettering Cancer Center has published a study that provides new insight into genetic changes

Cancer biologist Robert Benezra explains angiogenesis, the process by which new blood vessels form, and how it relates to cancer research.

… Thursday, March 13, 2014 Summary Cancer biologist Robert Benezra explains angiogenesis, the process by which new blood vessels form, and how it relates to cancer research. Angiogenesis is the process by which new blood vessels form, allowing the delivery of oxygen and nutrients to the body’s tissues.